Recurrence, not growth, is the consumer IPO qualifier

Nutrabolt, the parent of C4 Energy, is reportedly working with JPMorgan, Goldman Sachs, and Bank of America on an IPO valued around $1 billion, as Drew Fallon and others reporting have tracked.

The cold-pressed juice brand Suja has filed to go public. The supplement brand IM8, a Skio merchant, is already trading through its Nasdaq-listed parent, Prenetics. In the same window, the apparel brand Reformation has also filed to go public, with a backlog of scaled clothing labels lined up behind it.

Most of the coverage reads all of this as one story: direct-to-consumer is back. But is it? One of these cohorts sells demand a bank can underwrite. The other sells the same one-time-purchase model that took Allbirds from a $4 billion valuation to a roughly $39 million sale.

So what separates the consumer brands that hold their value in public markets from the ones that crater? It isn’t growth, and it isn’t even loyalty. It’s recurrence.

Across more than 20,000 subscription brands, over half of replenishment reorders land within two days of the 30-day mark: supplements at 53.7%, coffee and tea at 53.2%, health and wellness at 51.8%.

That’s demand you can forecast, order after order.

The apparel brands that cratered after their IPOs never had it. They had a great launch and then a hopeful guess about the next purchase. If you’re building toward a raise or an exit, a predictable reorder base is worth more than a growth spike, because predictability is the thing a public-market investor can actually price.

Two IPO windows are open, and they’re not the same bet

The consumer brands going public in 2026 split cleanly into two groups.

Group A: recurring-demand CPG that reorders on a schedule.

Group B: one-time-purchase DTC that has to re-win every customer from scratch.

The first group is the one lining up now on the strength of predictable consumption. Nutrabolt and C4 in sports nutrition, Suja in juice, IM8 in supplements. These are businesses where the same customer comes back on a cadence, which is exactly the demand a banker can model into a forecast.

The second group is a re-run of the 2010s DTC apparel playbook, led by Reformation with names like Vuori, Alo, SKIMS, and Gymshark reportedly waiting behind it. It’s the same one-time-purchase model as the last cohort that tried this. And the last cohort is the cautionary tale.

The post-IPO numbers for that cohort are ugly.

One-time-purchase DTC brand	What happened after the IPO
Allbirds	~$4B valuation to a ~$39M sale
Warby Parker	Down ~75% from its IPO price
Casper	Down ~57%, later taken private

Those figures are from public-market reporting, not from Recharge, and we only see subscription brands, so we can’t measure these companies’ churn directly.

But the public post-mortems all point the same way. These brands were built on one hero product and cheap paid acquisition, with no real engine to bring an existing customer back for the next order.

When acquisition stopped being cheap, the math broke.

They paid more and more to replace customers who were never going to reorder on their own, and the losses compounded from there. The scramble that followed is its own tell.

Allbirds pushed into apparel and an Onion-worthy AI pivot.

Peloton kept bolting on new bets after the COVID-driven home equipment bubble popped.

None of it replaced the one thing they never built: a reason for the same customer to come back on a schedule.

What underwritable recurring demand actually looks like

Across more than 20,000 subscription brands using Recharge, more than half of replenishment reorders land within two days of the 30-day mark, which is what makes the revenue forecastable.

Cadence predictability here is simple: it’s the share of real reorder intervals, measured subscriber by subscriber, that land in a tight band around the monthly mark.

Across the largest replenishment verticals, the numbers cluster in the same place.

Vertical	Median cadence	Within +/-2 days (28-32)	Within +/-5 days (25-35)
Supplements & Vitamins	30 days	53.7%	58.6%
Coffee & Tea	30 days	53.2%	56.6%
Health & Wellness	30 days	51.8%	54.8%

For supplements and vitamins, 53.7% of reorders land within two days of the 30-day mark, and 58.6% within five. The other verticals tell the same story, 55 to 59% within five days. This is the difference between a business a bank can model and a growth-story brand that can only promise its next launch will land.

When you can tell an investor that a majority of next month’s orders are already on a clock, you’re describing revenue, not hope. It’s also why this kind of demand shows up so clearly in subscription analytics and in our annual Subscription Trend Report: the pattern is consistent enough to plan around.

Recurrence beats loyalty: why a harder-churning category can still be IPO-ready

Sports-nutrition subscriptions churn harder than the platform average, yet they reorder on the same monthly clock, so the underwritable asset is recurrence, not loyalty. The intuitive answer, that you want the lowest churn and the most loyal customers, turns out to be the wrong test.

The clearest case is a category that fails the loyalty test but passes the recurrence one.

Segment	Active churn per cycle	Reorder clock
Platform-wide	~15.7%	~30 days
Sports nutrition (pre-workout, creatine, BCAA, whey, energy)	~21.5%	~31 days

Sports nutrition carries an active-churn rate of about 21.5% of cycles, well above the roughly 15.7% platform average.

By the loyalty test, that looks shaky.

But the demand that stays reorders like clockwork, on the same roughly 31-day cadence as everything else. And Nutrabolt is reportedly lining up a billion-dollar IPO on exactly this base. A category can churn harder than average and still be underwritable, because the subscriber demand that remains shows up on schedule.

That’s also why defending the recurring base matters so much: the leverage isn’t in chasing a lower headline churn number, it’s in keeping the customers who reorder, which is the whole job of churn prevention.

What to do if you’re building toward a raise or an exit

A predictable reorder clock and a durable post-trial base are worth more to a buyer than a new-customer spike, because they’re what can actually be underwritten. The lesson for operators and founders is to build for recurrence, not just growth.

Three things to take from the data:

1. Measure your reorder-interval concentration, not just your reorder rate. How tightly do your reorders cluster around your billing cadence? That concentration is the forecastable asset.
2. Watch retention past the first reorder, by cohort, against category benchmarks. Clearing the trial cliff is what turns a strong launch into a compounding base.
3. Defend the recurring base rather than chasing a lower churn headline. Even a harder-churning category clears the bar when the demand that stays is predictable.

Growth gets you noticed. Recurrence is what public markets, and acquirers, can actually price. Build the reorder base, protect it, and you’re building the one asset that holds its value whether or not you ever ring the bell.

About this report

This is based on aggregate subscription data from more than 20,000 Recharge brands, looking at renewal cycles over the trailing twelve months across the largest replenishment verticals: supplements and vitamins, coffee and tea, health and wellness, and pet. Sports nutrition here is a keyword-defined slice of supplements (pre-workout, creatine, BCAA, whey, and energy). We measure reorder predictability as the share of actual reorder intervals that land within a few days of the 30-day mark. One honest limit: Recharge only sees subscription brands, so the contrast with one-time-purchase apparel is read from those companies’ public-market results, not from our data. External IPO and valuation figures come from public reporting.

FAQ

Does recurring revenue make a consumer brand more valuable to investors? Yes. Recurring, predictable demand is easier to forecast and underwrite, which is why replenishment CPG brands are going public on it while one-time-purchase DTC brands were repriced down after their IPOs.

Does a subscription brand need low churn to be IPO-ready? Not necessarily. Sports-nutrition subscriptions churn harder than the platform average yet still reorder on a predictable monthly clock, so the underwritable asset is recurrence, not loyalty.

What is IM8, and does it trade as a stock? IM8 is a premium supplement brand co-founded with David Beckham and launched in late 2024. It doesn’t trade on its own. Its Nasdaq-listed parent, Prenetics (ticker PRE), pivoted to make IM8 its core business and guided to roughly $190 million or more in IM8 revenue for 2026.